GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

GSK plcNYSE: GSK

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses growth accelerates

Q2 FY2026 operating expenses of £5.66B rose 49.1% year over year, ahead of the -1.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 63.6% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.

Context

  • Operating expenses amounted to 46.9% of revenue in FY2025, down 11.5 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +49.1% holds above the trailing-twelve-month pace of -1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
£5.66B+63.6% QoQ
Last fiscal yearDec 2025
£15.31B-16.4% YoY
LTMJun 2026
£17.27B-1.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.1%——
1 year-16.4%——
3-year CAGR+4.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

GBP · from the income statement

Latest · FY2025
15.31B GBP
Year-over-year change
-16.4%
4-year CAGR
+5.9%

Operating Expenses vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.0% is the 9th highest of 10, against a peer median of +5.1%.
  • Operating expenses amounts to 52.0% of revenue for GSK, versus a peer median of 43.9%.
GSK Competitors
Operating Expenses for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 123.58B DKK+3.8%+18.5%37.5%
JNJJohnson & JohnsonLTM Sep 2026$42.83B USD+10.7%+3.7%43.1%
MRKMerck & Co., Inc.LTM Jun 2026$38.99B USD+46.3%-0.5%58.7%
AZNAstraZeneca PLCLTM Sep 2026$35.08B USD-0.0%+6.8%56.4%
PFEPfizer Inc.LTM Jun 2026$29.59B USD+0.7%+0.5%46.5%
SNYSanofiLTM Jun 2026€28.48B EUR+24.0%+9.1%58.2%
LLYEli Lilly and CompanyLTM Jun 2026$26.83B USD+24.4%+22.6%33.7%
NVSNovartis AGLTM Jun 2026$24.42B USD-3.8%+0.2%43.9%
GSKGSK plcLTM Jun 2026£17.27B GBP-1.0%+4.7%52.0%
AMGNAmgen Inc.LTM Jun 2026$15.05B USD+5.1%+14.0%39.5%
Peer median (excluding GSK) —+5.1%+6.8%43.9%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.